Literature DB >> 28432270

Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies.

V R V Yance1, J A M Marcondes1, M P Rocha1, C R G Barcellos1, W S Dantas1, A F A Avila2, R H Baroni2, F M Carvalho3, S A Y Hayashida4, B B Mendonca1, S Domenice1.   

Abstract

BACKGROUND: The presence of virilizing signs associated with high serum androgen levels in postmenopausal women is rare. Virilizing ovarian tumors (VOTs) and ovarian stromal hyperthecosis (OH) are the most common etiologies in virilized postmenopausal women. The differential diagnosis between these two conditions is often difficult.
OBJECTIVE: To evaluate the contribution of clinical features, hormonal profiles and radiological studies to the differential diagnosis of VOT and OH.
DESIGN: A retrospective study.
SETTING: A tertiary center. MAIN OUTCOME MEASURES: Clinical data, hormonal status (T, E2, LH and FSH), pelvic images (transvaginal sonography and MRI) and anatomopathology were reviewed. PATIENTS: Thirty-four postmenopausal women with a diagnosis of VOT (13 women) and OH (21 women) were evaluated retrospectively.
RESULTS: Clinical signs of hyperandrogenism were more prevalent in the VOT group than the OH group. Although the VOT group showed higher T and E2 levels and lower gonadotropin levels than the OH group, a great overlap occurred among the hormone levels. A pelvic MRI provided an accurate differentiation of these two conditions.
CONCLUSION: In this group of patients, the main features contributing to the differential diagnosis of VOT and OH were serum levels of testosterone and gonadotropins and the presence of an ovarian nodule identified on the MRI. Although the association of clinical, hormonal and radiological features contributes to the differential diagnosis of these two conditions, histopathological analysis remains the gold standard for the diagnosis of ovarian hyperandrogenism in postmenopausal women.
© 2017 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28432270     DOI: 10.1530/EJE-17-0111

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

1.  Severe hyperandrogenism due to ovarian hyperthecosis in a young woman.

Authors:  Alpesh Goyal; Rakhi Malhotra; Vidushi Kulshrestha; Garima Kachhawa
Journal:  BMJ Case Rep       Date:  2019-12-17

Review 2.  Postmenopausal Hyperandrogenism: Evaluation and Treatment Strategies.

Authors:  Adnin Zaman; Micol S Rothman
Journal:  Endocrinol Metab Clin North Am       Date:  2021-01-11       Impact factor: 4.741

3.  An Occult Leydig Cell Tumour in a Postmenopausal Woman Presenting with Alopecia and Hirsutism: A Case Report.

Authors:  Shuann Shwana; Natasha Shrikrishnapalasuriyar; Win Yin; Monica Vij; Atul Kalhan
Journal:  touchREV Endocrinol       Date:  2021-04-28

4.  Virilising ovarian tumors: a single-center experience.

Authors:  Manjeetkaur Sehemby; Prachi Bansal; Vijaya Sarathi; Ashwini Kolhe; Kanchan Kothari; Swati Jadhav-Ramteke; Anurag R Lila; Tushar Bandgar; Nalini S Shah
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

5.  Aldosterone- and cortisol-cosecreting adrenal adenoma, ovarian hyperthecosis and breast cancer.

Authors:  John J Orrego; Joseph A Chorny
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-09-23

Review 6.  Gonadotropin-Releasing Hormone Analogue Stimulation Test Versus Venous Sampling in Postmenopausal Hyperandrogenism.

Authors:  Eng-Loon Tng; Jeanne May May Tan
Journal:  J Endocr Soc       Date:  2020-11-05

Review 7.  Approach to androgen excess in women: Clinical and biochemical insights.

Authors:  Leanne Cussen; Tara McDonnell; Gillian Bennett; Christopher J Thompson; Mark Sherlock; Michael W O'Reilly
Journal:  Clin Endocrinol (Oxf)       Date:  2022-03-29       Impact factor: 3.523

8.  Virilization and metabolic disease in postmenopausal women related to ovarian hyperplasia and hypertecosis

Authors:  Agustina Lucila Larrea; Vicente Ricardo González; Pablo Knoblovits; Santiago José Gil
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2021-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.